View ValuationBioter 将来の成長Future 基準チェック /06現在、 Bioterの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Construction 収益成長10.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceNew Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceBoard Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.お知らせ • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United KingdomIs New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bioter は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ATSE:BIOT - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20241-21-12-12N/A9/30/20241-17-11-11N/A6/30/20240-12-11-10N/A3/31/20240-12-8-8N/A12/31/20230-12-6-6N/A9/30/20230-11-6-6N/A6/30/20230-9-7-7N/A3/31/20230-10-8-8N/A12/31/20220-10-9-9N/A9/30/20220-10-8-8N/A6/30/20220-10-7-7N/A3/31/20220-10-7-7N/A12/31/20210-9-6-6N/A9/30/202100-7-7N/A6/30/202108-7-7N/A3/31/202107-8-8N/A12/31/202006-9-9N/A9/30/20200-2-9-9N/A6/30/20200-11-8-8N/A3/31/20200-10-7-7N/A12/31/20190-9-6-6N/A9/30/20190-11-8-8N/A6/30/20190-13-10-10N/A3/31/20190-13-9-9N/A12/31/20180-13-7-7N/A9/30/20180-15N/A-9N/A6/30/20180-18N/A-11N/A3/31/20180-18N/A-12N/A12/31/20170-18N/A-14N/A9/30/20170-18N/A-11N/A6/30/20171-18N/A-8N/A3/31/20171-18N/A-8N/A12/31/20161-18N/A-7N/A9/30/20160-16N/A-6N/A6/30/20160-10N/A-7N/A3/31/20160-10N/A-9N/A12/31/20151-10N/A-9N/A9/30/20153-14N/A-11N/A6/30/20154-14N/A-8N/A3/31/20155-12N/A-8N/A12/31/20145-14N/A-10N/A9/30/20144-11N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIOTの予測収益成長が 貯蓄率 ( 2.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIOTの収益がGreek市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIOTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIOTの収益がGreek市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BIOTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIOTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/27 00:02終値2025/05/30 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioter S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).
お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
New Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).
Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...
Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.
お知らせ • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United Kingdom
Is New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.